ESMO: AbbVie's PARP veliparib finally gets a win, but can it compete? - FierceBiotech

1. ESMO: AbbVie's PARP veliparib finally gets a win, but can it compete?  FierceBiotech
2. PARP Inhibitors Move Into First-Line for Ovarian Cancer  Medscape
3. GlaxoSmithKline Says Ovarian Cancer Study Validates Tesaro Acquisition  Wall Street Journal
4. Frontline Olaparib/Bevacizumab Maintenance Combo Extends PFS in Ovarian Cancer  OncLive
5. Cediranib/Olaparib Combo Shows Promise in Platinum-Resistant Ovarian Cancer  OncLive
6. View full coverage on Google News

ESMO: AbbVie's PARP veliparib finally gets a win, but can it compete? - FierceBiotech
Read More


Bagikan Berita Ini